Mechanisms of Drug Action

Why This Matters

Every drug you'll study in pharmacology works because it interacts with the body at a molecular level. The mechanisms covered here form the foundation for understanding drug classes from antihypertensives to chemotherapeutics. When you encounter a new drug, your first question should always be: "What is this drug doing at the cellular or molecular level?"

These mechanisms demonstrate core principles like receptor theory, enzyme kinetics, membrane physiology, and signal transduction. Exam questions rarely ask you to simply name a mechanism. Instead, they want you to predict what happens when a drug binds, explain why one drug works differently than another, or troubleshoot why a patient isn't responding to therapy. Don't just memorize definitions. Know what molecular target each mechanism involves and what physiological outcome it produces.

---

Receptor-Based Mechanisms

Most drugs work by interacting with receptors, which are specialized proteins that recognize specific molecules and translate that recognition into cellular responses. The type of receptor determines the speed, duration, and nature of the drug's effect.

Receptor Binding and Activation

• Receptor specificity means drugs bind to particular receptor types, and the receptor class determines how fast the response happens:
  • Ligand-gated ion channels respond in milliseconds (they directly open an ion pore)
  • G-protein coupled receptors (GPCRs) respond in seconds to minutes (they work through second messenger cascades)
  • Enzyme-linked receptors (like receptor tyrosine kinases) respond in minutes to hours
  • Nuclear/intracellular receptors respond in hours to days (they alter gene transcription)
• Binding reversibility affects duration of action. Most drugs bind reversibly, so their effects fade as the drug dissociates. Irreversible binding produces longer-lasting effects but may require synthesis of entirely new receptor proteins for recovery.
• Receptor location matters. Cell surface receptors mediate rapid responses, while intracellular or nuclear receptors alter gene transcription for slower, sustained effects.

Agonist and Antagonist Effects

Agonists activate receptors to mimic endogenous ligands and produce a biological response. The term efficacy describes how well an agonist activates the receptor once bound. A full agonist produces the maximal possible response; a partial agonist produces submaximal activation even at full receptor occupancy. Buprenorphine is a classic partial agonist example: it activates opioid receptors enough to reduce withdrawal symptoms but has a ceiling on its effects, which lowers overdose risk compared to full agonists like morphine.

Antagonists bind receptors without activating them. They work by preventing endogenous ligands or other drugs from reaching the receptor. A competitive antagonist (like naloxone at opioid receptors) can be overcome by increasing the concentration of agonist. A non-competitive antagonist cannot be overcome regardless of how much agonist is present, because it either binds irreversibly or binds at a different site that changes receptor function.

Allosteric Modulation

The orthosteric site is where the endogenous ligand normally binds. An allosteric site is a separate location on the same receptor. Drugs that bind allosteric sites can fine-tune receptor activity without directly competing with the body's own signaling molecules.

• Positive allosteric modulators (PAMs) enhance the effect of the primary ligand when it's present
• Negative allosteric modulators (NAMs) reduce the primary ligand's effect

The clinical advantage is that allosteric modulators tend to preserve the body's natural signaling patterns, which can mean fewer side effects compared to direct agonists or antagonists.

---

Enzyme-Targeted Mechanisms

Enzymes catalyze biochemical reactions throughout the body, making them powerful drug targets. By inhibiting specific enzymes, drugs can increase or decrease concentrations of key molecules in metabolic pathways.

Enzyme Inhibition

Competitive inhibitors bind the enzyme's active site and compete directly with the natural substrate. Their effects can be overcome by increasing substrate concentration, because the substrate and drug are essentially fighting for the same spot.

Non-competitive inhibitors bind elsewhere on the enzyme and reduce its catalytic activity regardless of how much substrate is present. More substrate won't help because the inhibitor isn't blocking the active site; it's changing the enzyme's shape or function.

Some high-yield therapeutic examples:

• ACE inhibitors (e.g., lisinopril) block the conversion of angiotensin I to angiotensin II, lowering blood pressure
• Statins (e.g., atorvastatin) inhibit HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis
• MAO inhibitors block monoamine oxidase, preventing the breakdown of neurotransmitters like serotonin and norepinephrine

Antimetabolite Action

Antimetabolites are drugs that structurally resemble natural substrates closely enough to get incorporated into metabolic pathways, where they disrupt normal cellular processes. They're essentially molecular imposters.

• Methotrexate inhibits dihydrofolate reductase, blocking the production of tetrahydrofolate, which cells need to synthesize nucleotides for DNA. This is why leucovorin (a form of reduced folate) can rescue normal cells from methotrexate toxicity: it bypasses the blocked step entirely.
• 5-Fluorouracil (5-FU) inhibits thymidylate synthase, blocking thymidine production needed for DNA synthesis.

Because these drugs target DNA synthesis, they're most effective against rapidly dividing cells. That's what makes them useful in cancer chemotherapy, but it also explains their common toxicities in other rapidly dividing tissues like bone marrow (causing myelosuppression) and the GI lining (causing mucositis).

---

Membrane and Channel Mechanisms

Cell membranes control what enters and exits cells, and many drugs work by modifying this gatekeeping function. Ion channels and transport proteins are key targets for drugs affecting excitable tissues like neurons, cardiac muscle, and smooth muscle.

Ion Channel Modulation

Drugs can block, open, or modify ion channels that control the flow of $Na^+$, $K^+$, $Ca^{2+}$, and $Cl^-$ across membranes. The ion involved determines the physiological effect:

• Calcium channel blockers (e.g., amlodipine, verapamil) reduce $Ca^{2+}$ entry into cardiac and vascular smooth muscle cells, decreasing contractility and vascular tone
• Sodium channel blockers (e.g., lidocaine, carbamazepine) decrease neuronal excitability and cardiac conduction velocity by preventing $Na^+$ influx needed for action potential generation

An important concept here is state-dependent binding. Many channel blockers preferentially bind to channels in their open or inactivated states rather than their resting state. This means the drug has a stronger effect on cells that are firing rapidly (because their channels spend more time in open/inactivated states). That's why lidocaine preferentially suppresses abnormally rapid cardiac rhythms without shutting down normal conduction.

Transporter Interactions

Transport proteins move molecules across membranes, either against concentration gradients (active transport) or along them (facilitated diffusion). Drugs can inhibit or modify this activity.

SSRIs (selective serotonin reuptake inhibitors, like fluoxetine) block the serotonin reuptake transporter (SERT), preventing serotonin from being cleared out of the synapse. The result is increased synaptic serotonin concentration, which is the basis for their antidepressant effects.

Beyond direct therapeutic effects, transporter inhibition can also alter drug absorption, distribution, and elimination. For example, if Drug A inhibits a transporter that normally clears Drug B from the body, Drug B's levels will rise. This is a common source of drug-drug interactions.

Membrane Disruption

Some drugs physically disrupt lipid bilayers, causing cell lysis or altered permeability. This mechanism is particularly important for antimicrobials:

• Polymyxins and daptomycin target bacterial cell membranes
• Amphotericin B binds ergosterol in fungal membranes, creating pores that leak cellular contents

Selectivity depends on membrane composition differences between human cells and pathogens. Fungal membranes contain ergosterol while human membranes contain cholesterol. Amphotericin B has a higher affinity for ergosterol, which is what makes it useful as an antifungal, though some binding to cholesterol still occurs and explains its significant toxicity (especially nephrotoxicity).

---

Nucleic Acid and Signaling Mechanisms

Some drugs work at the level of genetic information or the signaling cascades that translate receptor activation into cellular responses. These mechanisms often produce profound, long-lasting effects on cell function.

DNA/RNA Interactions

Direct nucleic acid binding can inhibit replication, transcription, or translation. These mechanisms are exploited by many anticancer and antiviral agents. The three main approaches:

• Alkylating agents (e.g., cyclophosphamide) form covalent bonds with DNA bases, creating cross-links that prevent the strands from separating during replication
• Intercalating agents (e.g., doxorubicin) physically insert themselves between DNA base pairs, distorting the helix and blocking replication and transcription
• Nucleoside analogs (e.g., acyclovir) mimic normal nucleosides and get incorporated into a growing DNA chain during replication, but they lack the chemical group needed to attach the next nucleotide, causing chain termination. Acyclovir is selectively activated by viral thymidine kinase, which is why it targets virus-infected cells over normal cells.

Signal Transduction Pathways

When a receptor is activated at the cell surface, the signal gets amplified and diversified through intracellular signaling cascades. These cascades use second messengers like $cAMP$, $IP_3$, and $Ca^{2+}$, along with kinase enzymes that activate downstream proteins by adding phosphate groups.

Drugs can target specific points in these cascades:

• Kinase inhibitors like imatinib block BCR-ABL tyrosine kinase, an abnormal enzyme produced by the Philadelphia chromosome in chronic myeloid leukemia. By targeting this specific kinase, imatinib is far more selective than traditional chemotherapy.
• Phosphodiesterase (PDE) inhibitors like sildenafil prevent the breakdown of $cGMP$, prolonging its signaling effects (in this case, smooth muscle relaxation in pulmonary and penile vasculature).

Pathway crosstalk is worth understanding: signaling pathways don't operate in isolation. A drug targeting one pathway may have unexpected effects on others, which can explain both additional therapeutic benefits and adverse reactions.

---

Quick Reference Table

---

Self-Check Questions

1. A patient on warfarin starts taking a new medication and experiences increased bleeding. The new drug is described as a competitive inhibitor of the same enzyme warfarin targets. Explain why competitive inhibition at the same site would increase rather than decrease warfarin's effect, or identify what's wrong with this scenario.

2. SSRIs and cocaine both increase synaptic monoamine levels by blocking reuptake transporters. What differences in transporter selectivity and pharmacokinetics explain their very different clinical profiles?

3. Which two of the following mechanisms would you expect to produce the fastest onset of drug effect: nuclear receptor activation, ion channel blockade, enzyme inhibition, or G-protein coupled receptor activation? Explain your reasoning based on the signaling steps involved.

4. A cancer drug is described as an antimetabolite that inhibits dihydrofolate reductase. What cellular process is disrupted, why does this preferentially affect cancer cells, and how does leucovorin rescue work?

5. Explain why benzodiazepines have a ceiling effect for sedation while barbiturates can cause fatal respiratory depression, even though both enhance GABA signaling. Use the concept of allosteric modulation vs. direct channel activation in your answer.